|
METTL14 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
1.92519999941965E-10 |
| Normal-vs-Stage3 |
6.66133814775094E-16 |
| Normal-vs-Stage4 |
1.62614366416847E-12 |
| Stage1-vs-Stage2 |
8.115400E-01 |
| Stage1-vs-Stage3 |
3.157600E-01 |
| Stage1-vs-Stage4 |
1.061840E-02 |
| Stage2-vs-Stage3 |
6.550600E-01 |
| Stage2-vs-Stage4 |
1.258770E-01 |
| Stage3-vs-Stage4 |
1.693200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.64116999999964E-05 |
| Normal-vs-Asian |
6.3037997044546E-10 |
| Caucasian-vs-AfricanAmerican |
1.991430E-01 |
| Caucasian-vs-Asian |
4.811000E-01 |
| AfricanAmerican-vs-Asian |
5.272200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.63657976059994E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
1.519200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
5.006500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.454800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.335200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.691400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.580000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.483600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.775200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.409800E-02 |
| Classical-VS-Follicular |
4.827700E-02 |
| Classical-VS-Other |
1.296610E-01 |
| Classical-VS-Normal |
2.11880513134588E-11 |
| Tall-VS-Follicular |
8.195600E-01 |
| Tall-VS-Other |
4.702800E-01 |
| Tall-VS-Normal |
1.7063017665464E-12 |
| Follicular-VS-Other |
5.312600E-01 |
| Follicular-VS-Normal |
1.66844316140669E-12 |
| Other-VS-Normal |
8.00340000000066E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
8.74855743404623E-14 |
| N0-vs-N1 |
1.620830E-01 |
|
|
